October 2024
The worldwide recombinant human hair keratin protein market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2024 to 2034. This growth is driven by emerging trends and strong demand across key sectors. The increasing demand for hair health, incidences of bleeding disorders, and increasing investments in biotechnology drive the market.
Recombinant human hair keratin is a protein derived from recombinant DNA (rDNA) technology. The non-modifying properties like amino acids and molecular weight, high impurity, and complex composition of extracted keratin potentiate the development of recombinant keratin. Recombinant keratin overcomes these challenges, providing highly pure keratin for several purposes. The two main recombinant keratins include – human type Ⅰ hair keratin 37 and human type Ⅱ hair keratin 81.
Recombinant human hair keratin is most widely used to accelerate wound healing. It is reported to enhance cell proliferation and migration in vivo and improve wound healing to treat dermal wounds in vitro. Additionally, recombinant keratin proteins can enhance fibrin clot formation at the injury site and reduce bleeding time. It has also been studied to improve hair health. Additionally, recombinant keratin can be used in drug delivery and tissue engineering. The increasing incidences of chronic disorders, increasing cases of bleeding disorders, and growing research and development drive the market.
The growing biotechnology sector, driven by the latest innovations, technological advancements, and increasing investments and collaborations, augments the market. Biotech companies raised more than $34 billion globally in 2021. The growth of the biotech sector is fuelled by rising demand at both domestic and international levels. The market is also driven by growing research and development activities and increasing funding for biotech R&D. Additionally, increasing awareness about recombinant DNA technology boosts the market growth. Recombinant human keratin is also used in techniques such as ELISA, western blot, immunohistochemistry, and immunofluorescence. The rising demand for point-of-care diagnostics for identifying different diseases and drug development research increases the demand for recombinant keratin. The demand is also increasing due to increased focus on cell and gene therapy products.
e exorbitant prices of recombinant human hair keratin limit the affordability of consumers. The average cost of recombinant human hair keratin protein ranges from $300 to $4,000, depending on the concentration. The complexity of large-scale production results in increased costs. Additionally, the lack of proper research data highlighting its significance on humans hinders the market.
North America dominated the recombinant human hair keratin protein market in 2023. The increasing investments & collaborations, presence of key players, and state-of-the-art research & development activities drive the market. The US and Canada are the major contributors to the market. Key players such as Novus Biologicals, Abcam Ltd., PROGEN, OriGene, etc., are responsible for the growth of the market. The US Government’s policies and initiatives to advance biotechnology research in the region augment the market. The US Department of Health and Human Services invested $40 million in 2022 to expand the role of biomanufacturing of APIs and antibiotics. The market is also driven by the US FDA approvals of recombinant proteins. The US FDA has approved more than 130 recombinant proteins for clinical use.
Asia-Pacific is anticipated to grow fastest in the recombinant human hair keratin protein market during the forecast period. The growing research & development activities, increasing government funding, increasing incidences of bleeding disorders, favorable infrastructure, and affordable costs drive the market. Recombinant keratin is proven to promote dermal wound healing and enhance blood clotting. In China, there are approximately 65,000 individuals suffering from hemophilia, while India has the second-largest number of hemophilia patients globally, accounting for 136,000 cases. The demand for products promoting hair growth and reducing hair loss is rapidly rising in China, South Korea, and Japan. Companies such as Tsubaki use recombinant human keratin to create luxurious hair treatments that appeal to beauty-conscious consumers.
Europe also has the potential to drive the recombinant human hair keratin protein market. The increasing investments in the biotechnology sector fuel the market growth. Germany, Spain, France, and the UK account for major growth in the region. According to the Spanish Association of Biotechnology Companies, the impact of biotech companies on the Spanish GDP amounted to €11,183 million in 2021, representing 1% of GDP. The biotech companies invested around €1,038 million in R&D, representing more than 6% of total national investment. In Germany, €3.74 billion was invested in biotech R&D in 2023. Additionally, technological advancements, advanced research & development activities, and increasing awareness of hair health boost the market.
October 2024
September 2024
August 2024
Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.